TABLE 2

Recommended Vaccination Schedule and Intervals

SubgroupPrimary VaccinationBooster Dose
9–23 mo, with high-risk conditionsChildren with complement deficiencies2 doses of MCV4, 3 mo apartIf the first dose is received at 9 mo to 6 y of age and child remains at increased risk for meningococcal disease, child should receive an additional dose of MCV4 3 y after primary vaccination; boosters should be repeated every 5 y thereafter
Children with HIV, if another indication for vaccination exists2 doses of MCV4, 3 mo apart
All others in this age group recommended for vaccination (travelers to the “meningitis belt,” etc)2 doses of MCV4, 3 mo apart (infants receiving the vaccine before travel can receive the doses as early as 2 mo apart)
2–18 y, with high risk conditionsaChildren with complement deficiencies or functional or anatomic asplenia2 doses of MCV4, 2 mo apartIf the first dose is received at 7 y of age or older and child remains at increased risk for meningococcal disease, child should receive an additional dose of MCV4 5 y after primary vaccination; boosters should be repeated every 5 y thereafter
Children with HIV, if another indication for vaccination exists2 doses of MCV4, 2 mo apart
All others in this age group recommended for vaccination (travelers to the Meningitis Belt, etc)1 dose of MCV4
All other children aged 11–18 yRoutine vaccination with MCV4 at ages 11–12 yIf vaccinated at age 1112 y, should receive a 1-time booster dose at the age of 16 y
If vaccinated at age 1315 y, should receive a 1-time booster dose at the age of 16–18 y
  • Currently, there are currently 2 licensed MCV4 products. One product, Menactra, is manufactured by Sanofi Pasteur and is licensed for use in persons aged 9 months through 55 years of age. The second product, Menveo, is manufactured by Novartis Vaccines and Diagnostics, Inc and is licensed for use in persons aged 2 through 55 years of age. A meningococcal polysaccharide vaccine is also available. This product is licensed for use in persons 2 years of age and older and may be used when meningococcal conjugate vaccine is unavailable or contraindicated.

  • a Includes children who have complement (eg, C5–C9, properdin, factor H, or factor) deficiencies or anatomic or functional asplenia and children with HIV infection; travelers to or residents of countries in which meningococcal disease is hyperendemic or epidemic; and children who are part of a community outbreak of a vaccine-preventable serogroup.